{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Carisma Therapeutics, Inc.
Is Carisma Therapeutics, Inc. technically bullish or bearish?
As of June 20, 2025, Carisma Therapeutics, Inc. shows a mildly bearish trend influenced by daily moving averages, despite mixed signals from weekly and monthly indicators.
Who are in the management team of Carisma Therapeutics, Inc.?
As of March 2022, the management team of Carisma Therapeutics, Inc. includes Dr. Jay Duker (Independent Chairman), Mr. Thomas Cannell (President and CEO), and several independent directors: Ms. Carrie Bourdow, Ms. Jane Henderson, Mr. Jason Keyes, and Mr. Daniel Lynch.
What does Carisma Therapeutics, Inc. do?
Carisma Therapeutics, Inc. is a late-stage clinical company developing antibody-drug conjugate therapies for cancer, with a market cap of $18.80 million and recent net sales of $4 million. As of March 2025, it reported a net profit loss of $9 million.
How big is Carisma Therapeutics, Inc.?
As of Jun 18, Carisma Therapeutics, Inc. has a market capitalization of 18.80 million, categorizing it as a Micro Cap company. As of Jun 24, net sales for the latest four quarters are 19.96 million, with a net profit of -50.77 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
